Market icon
Finance·Actions

Johnson & Johnson (JNJ) battra-t-il les bénéfices trimestriels ?

Market icon
Finance·Actions

Johnson & Johnson (JNJ) battra-t-il les bénéfices trimestriels ?

Oui

88% chance
Polymarket
NOUVEAU

Oui

88% chance
Polymarket
NOUVEAU
As of market creation, Johnson & Johnson is estimated to release earnings on April 14, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.68 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.68 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS. Trader consensus on Polymarket prices a strong 87.5% implied probability for Johnson & Johnson (JNJ) to beat Q1 2026 non-GAAP EPS consensus of $2.68, driven by a Zacks Earnings Surprise Prediction (ESP) of +3.91%, signaling recent upward analyst estimate revisions amid robust Innovative Medicine sales momentum from blockbusters like Darzalex. JNJ's Q4 2025 revenue beat of $24.56 billion exceeded forecasts by nearly 200 basis points, with full-year 2026 guidance for $99.5–$100.5 billion in operational sales surpassing Street expectations of $98.9 billion. This reflects sustained mid-single-digit growth and margin resilience, building on a history of frequent earnings beats. Key focus ahead of the April 14 release: quarterly revenue trends and pipeline updates.

As of market creation, Johnson & Johnson is estimated to release earnings on April 14, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.68 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.68 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents.

If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)

If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”

Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Volume
$2,470
Date de fin
14 avr. 2026
Marché ouvert
Mar 30, 2026, 7:54 PM ET

Source de résolution

https://seekingalpha.com/

Resolver

0x65070BE91...
As of market creation, Johnson & Johnson is estimated to release earnings on April 14, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.68 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.68 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
As of market creation, Johnson & Johnson is estimated to release earnings on April 14, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.68 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.68 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS. Trader consensus on Polymarket prices a strong 87.5% implied probability for Johnson & Johnson (JNJ) to beat Q1 2026 non-GAAP EPS consensus of $2.68, driven by a Zacks Earnings Surprise Prediction (ESP) of +3.91%, signaling recent upward analyst estimate revisions amid robust Innovative Medicine sales momentum from blockbusters like Darzalex. JNJ's Q4 2025 revenue beat of $24.56 billion exceeded forecasts by nearly 200 basis points, with full-year 2026 guidance for $99.5–$100.5 billion in operational sales surpassing Street expectations of $98.9 billion. This reflects sustained mid-single-digit growth and margin resilience, building on a history of frequent earnings beats. Key focus ahead of the April 14 release: quarterly revenue trends and pipeline updates.

As of market creation, Johnson & Johnson is estimated to release earnings on April 14, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.68 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.68 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents.

If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)

If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”

Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Volume
$2,470
Date de fin
14 avr. 2026
Marché ouvert
Mar 30, 2026, 7:54 PM ET

Source de résolution

https://seekingalpha.com/

Resolver

0x65070BE91...
As of market creation, Johnson & Johnson is estimated to release earnings on April 14, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.68 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.68 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.

Méfiez-vous des liens externes.

Questions fréquentes

« Johnson & Johnson (JNJ) battra-t-il les bénéfices trimestriels ? » est un marché de prédiction sur Polymarket avec 2 résultats possibles où les traders achètent et vendent des parts selon ce qu'ils pensent qu'il se passera. Le résultat en tête actuel est « Johnson & Johnson (JNJ) va-t-elle dépasser les prévisions de bénéfices trimestriels ? » à 88%. Les prix reflètent des probabilités en temps réel de la communauté. Par exemple, une part cotée à 88¢ implique que le marché attribue collectivement une probabilité de 88% à ce résultat. Ces cotes changent en permanence. Les parts du résultat correct sont échangeables contre $1 chacune lors de la résolution du marché.

« Johnson & Johnson (JNJ) battra-t-il les bénéfices trimestriels ? » est un marché nouvellement créé sur Polymarket, lancé le Mar 30, 2026. En tant que marché récent, c'est votre opportunité d'être parmi les premiers traders à définir les cotes et établir les premiers signaux de prix du marché. Vous pouvez également ajouter cette page à vos favoris pour suivre le volume et l'activité de trading au fil du temps.

Pour trader sur « Johnson & Johnson (JNJ) battra-t-il les bénéfices trimestriels ? », parcourez les 2 résultats disponibles sur cette page. Chaque résultat affiche un prix actuel représentant la probabilité implicite du marché. Pour prendre position, sélectionnez le résultat que vous estimez le plus probable, choisissez « Oui » pour trader en sa faveur ou « Non » pour trader contre, entrez votre montant et cliquez sur « Trader ». Si votre résultat choisi est correct lors de la résolution, vos parts « Oui » rapportent $1 chacune. S'il est incorrect, elles rapportent $0. Vous pouvez également vendre vos parts avant la résolution.

Le favori actuel pour « Johnson & Johnson (JNJ) battra-t-il les bénéfices trimestriels ? » est « Johnson & Johnson (JNJ) va-t-elle dépasser les prévisions de bénéfices trimestriels ? » à 88%, ce qui signifie que le marché attribue une probabilité de 88% à ce résultat. Ces cotes sont mises à jour en temps réel à mesure que les traders achètent et vendent des parts. Revenez fréquemment ou ajoutez cette page à vos favoris.

Les règles de résolution de « Johnson & Johnson (JNJ) battra-t-il les bénéfices trimestriels ? » définissent exactement ce qui doit se produire pour que chaque résultat soit déclaré gagnant, y compris les sources de données officielles utilisées pour déterminer le résultat. Vous pouvez consulter les critères de résolution complets dans la section « Règles » sur cette page au-dessus des commentaires. Nous recommandons de lire attentivement les règles avant de trader, car elles précisent les conditions exactes, les cas particuliers et les sources.